Quick Answer
COGNITION THERAPEUTICS INC reported Net Income of -$23.49 million for fiscal year 2025.
COGNITION THERAPEUTICS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$23.49M +30.9% |
-$33.97M -31.7% |
-$25.79M -20.5% |
-$21.40M -82.6% |
-$11.72M -49.5% |
-$7.84M |
| Diluted EPS | -$0.32 +62.8% |
-$0.86 +0.0% |
-$0.86 +5.5% |
-$0.91 +70.9% |
-$3.13 +86.8% |
-$23.76 |
| Total Assets | $48.39M +60.1% |
$30.23M -14.0% |
$35.16M -30.3% |
$50.42M -14.7% |
$59.14M +730.7% |
$7.12M |
| Cash and Equivalents | $36.81M +47.2% |
$25.01M -16.4% |
$29.92M -28.0% |
$41.56M -24.0% |
$54.72M +954.6% |
$5.19M |
| Stockholders Equity | $34.27M +82.8% |
$18.75M -23.4% |
$24.47M -39.2% |
$40.25M -21.5% |
$51.27M +175.2% |
-$68.18M -16.7% |
| R&D Expense | $37.19M -10.8% |
$41.68M +12.0% |
$37.20M +22.7% |
$30.32M +63.3% |
$18.57M +44.1% |
$12.89M |
| Operating Income | -$47.80M +11.4% |
-$53.97M -6.4% |
-$50.72M -16.5% |
-$43.55M -52.3% |
-$28.60M -64.3% |
-$17.41M |
| Shares Outstanding | 88.90M +48.5% |
59.85M +86.1% |
32.17M +10.9% |
28.99M +30.4% |
22.23M +4025.9% |
538,793 |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$4.93M | +50.4% | +26.8% |
| Diluted EPS | September 30, 2025 | -$0.06 | +76.0% | +45.5% |
| Total Assets | September 30, 2025 | $43.40M | +57.3% | +121.2% |
| Cash and Equivalents | September 30, 2025 | $39.33M | +78.7% | +266.1% |
| Stockholders Equity | September 30, 2025 | $36.53M | +152.2% | +419.7% |
| R&D Expense | September 30, 2025 | $3.77M | -66.9% | -67.1% |
| Operating Income | September 30, 2025 | -$6.38M | +55.9% | +54.4% |
| Shares Outstanding | September 30, 2025 | 88.27M | +116.3% | +35.9% |
- COGNITION THERAPEUTICS INC reported Net Income of -$23.49 million for fiscal year 2025.
- COGNITION THERAPEUTICS INC showed an increase of +30.9% in Net Income compared to the prior fiscal year.
- COGNITION THERAPEUTICS INC reported Diluted EPS of $0.32 per share (loss) for fiscal year 2025.
- COGNITION THERAPEUTICS INC showed an increase of +62.8% in Diluted EPS compared to the prior fiscal year.
- COGNITION THERAPEUTICS INC reported Total Assets of $48.39 million for fiscal year 2025.
- COGNITION THERAPEUTICS INC showed an increase of +60.1% in Total Assets compared to the prior fiscal year.
- COGNITION THERAPEUTICS INC reported Cash and Equivalents of $36.81 million for fiscal year 2025.
- COGNITION THERAPEUTICS INC showed an increase of +47.2% in Cash and Equivalents compared to the prior fiscal year.
- COGNITION THERAPEUTICS INC reported Stockholders Equity of $34.27 million for fiscal year 2025.
- COGNITION THERAPEUTICS INC showed an increase of +82.8% in Stockholders Equity compared to the prior fiscal year.
- COGNITION THERAPEUTICS INC reported R&D Expense of $37.19 million for fiscal year 2025.
- COGNITION THERAPEUTICS INC showed a decrease of -10.8% in R&D Expense compared to the prior fiscal year.
- COGNITION THERAPEUTICS INC reported Operating Income of -$47.80 million for fiscal year 2025.
- COGNITION THERAPEUTICS INC showed an increase of +11.4% in Operating Income compared to the prior fiscal year.
- COGNITION THERAPEUTICS INC reported Shares Outstanding of 88.90 million shares for fiscal year 2025.
- COGNITION THERAPEUTICS INC showed an increase of +48.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: